Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Body Composition Is an Independent Predictor of Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib ; volume:8 ; number:4 ; year:2019 ; pages:255-270
Liver cancer ; 8, Heft 4 (2019), 255-270
- Creator
-
Labeur, Tim A.
van Vugt, Jeroen L.A.
Ten Cate, David W.G.
Takkenberg, R. Bart
IJzermans, Jan N.M.
Groot Koerkamp, Bas
de Man, Robert A.
van Delden, Otto M.
Eskens, Ferry A.L.M.
Klümpen, Heinz-Josef
- DOI
-
10.1159/000493586
- URN
-
urn:nbn:de:101:1-2019080100140237376917
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:39 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Labeur, Tim A.
- van Vugt, Jeroen L.A.
- Ten Cate, David W.G.
- Takkenberg, R. Bart
- IJzermans, Jan N.M.
- Groot Koerkamp, Bas
- de Man, Robert A.
- van Delden, Otto M.
- Eskens, Ferry A.L.M.
- Klümpen, Heinz-Josef
Other Objects (12)
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment
Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib
Sorafenib response in hepatocellular carcinoma therapy : introducing new possibilities with Cdk5 inhibition
Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment
Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib
Sorafenib response in hepatocellular carcinoma therapy : introducing new possibilities with Cdk5 inhibition
Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma
Improved survival prediction and comparison of prognostic models for patients with hepatocellular carcinoma treated with sorafenib
Unresectable Ectopic Hepatocellular Carcinoma Treated with Sorafenib
Complete pathological regression of hepatocellular carcinoma with portal vein thrombosis treated with sorafenib
Hepatocellular Carcinoma with Distant Metastasis Cured by 20-Day Sorafenib Treatment
Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma
Hepatic Arterial Infusion Chemotherapy versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Pancreatic Atrophy in Hepatocellular Carcinoma Patients Receiving Long-Term Treatment with Sorafenib
Sorafenib response in hepatocellular carcinoma therapy : introducing new possibilities with Cdk5 inhibition
Radiologic Response Combined with Dermatologic Toxicities is the Most Robust Predictor of Survival Benefits in Patients with Inoperable Hepatocellular Carcinoma After Transarterial Chemoembolization Plus Sorafenib Therapy
The safety and efficacy of transarterial chemoembolization combined with sorafenib and sorafenib mono-therapy in patients with BCLC stage B/C hepatocellular carcinoma
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
Schedule-dependent antitumor effects of 5-fluorouracil combined with sorafenib in hepatocellular carcinoma